What Is Compensated Advanced Chronic Liver Disease?

Compensated advanced chronic liver disease, usually shortened to cACLD, is a term introduced in 2015 to describe the broad spectrum between severe liver scarring (advanced fibrosis) and full-blown cirrhosis in people who have not yet developed any overt complications. The word “compensated” is the key: the liver is damaged, sometimes heavily, but it is still managing to do its job well enough that you feel essentially normal. The concept was created partly because the old sharp line between “fibrosis” and “cirrhosis” did not reflect how patients actually progressed, and partly because non-invasive tools had become good enough to identify these patients without a biopsy.

Why the Term Exists

For decades, hepatologists talked about liver disease in two buckets: fibrosis (mild to moderate scarring) and cirrhosis (severe, architecture-warping scarring confirmed on biopsy). The problem was that the real-world boundary between advanced fibrosis and early cirrhosis is blurry, and distinguishing between the two often did not change what doctors needed to do. Both groups face rising pressure in the portal vein, both need monitoring, and both can deteriorate if the underlying cause of liver injury is not addressed. The Baveno VI consensus in 2015 proposed cACLD as a single clinical concept that captures both stages in patients without symptoms, largely because newer tools like transient elastography made it possible to flag these patients without the risks and costs of a liver biopsy.

Compensated Versus Decompensated

Advanced chronic liver disease splits into two main stages with dramatically different outlooks. In the compensated stage, you have significant liver damage but no clinical complications; the prognosis is relatively favorable. In the decompensated stage, complications have appeared, and survival drops steeply.

The complications that mark the shift to decompensation include fluid accumulation in the abdomen (ascites), bleeding from swollen veins in the esophagus or stomach (variceal bleeding), and episodes of confusion caused by toxins the liver can no longer clear (hepatic encephalopathy).¹ A first decompensation event is widely regarded as a turning point: median survival in compensated cirrhosis is roughly ten to twelve years, but once decompensation occurs it can fall to just one to two years.² That enormous gap in prognosis is why so much clinical energy goes into catching liver disease while it is still compensated and keeping it that way.

The Role of Portal Hypertension

The engine behind most complications of advanced liver disease is portal hypertension, which is elevated pressure in the portal vein, the large vessel that carries blood from the gut to the liver. As scar tissue accumulates, it physically increases resistance to blood flow through the liver.³ Blood backs up, pressures rise, and the body opens alternative routes (collateral veins, especially around the esophagus and stomach) that were never meant to handle that volume. When those fragile vessels rupture, variceal bleeding results. The same elevated pressure also drives fluid into the abdominal cavity, producing ascites.

The gold standard for measuring portal pressure is the hepatic venous pressure gradient, or HVPG. A value above 10 mmHg is defined as clinically significant portal hypertension (CSPH), and that threshold is where complications can start to appear.⁴ HVPG measurement requires threading a catheter through the jugular vein into the hepatic veins, however, so in practice it is reserved for specialized centers and research settings. The push in recent years has been to approximate that information non-invasively.

How cACLD Is Diagnosed Without a Biopsy

The diagnostic workup for cACLD has shifted decisively toward non-invasive tools, with liver stiffness measurement (LSM) by transient elastography at the center. The concept was introduced at the same time as the suggestion that specific stiffness thresholds could rule cACLD in or out.⁵ A stiffer liver means more scar tissue, and the measurement takes only a few minutes, is painless, and can be done in an outpatient clinic.

The original Baveno VI criteria set cutoffs at 10 and 15 kPa: a reading below 10 made cACLD unlikely, a reading above 15 made it likely, and values in between were indeterminate. Subsequent work refined those thresholds for specific populations. In patients with non-alcoholic fatty liver disease in Asia, for example, updated cutoffs showed comparable specificity but higher sensitivity for identifying cACLD compared with the original numbers.⁶

Beyond identifying cACLD itself, the Baveno VII consensus in 2022 extended the approach to estimate whether a patient has CSPH. The rule-out criterion combines a liver stiffness of 15 kPa or below with a platelet count at or above 150 × 10⁹/L. An individual patient data meta-analysis found that this combination had a pooled negative predictive value of 99% across all etiologies, meaning it essentially never misses significant portal hypertension when both numbers look reassuring.⁷ On the other end, a liver stiffness of 25 kPa or above is used to rule in CSPH.⁸

Risk Stratification Beyond a Single Number

Not everyone who meets the threshold for cACLD faces the same risk. There is growing evidence that the Baveno framework’s “Rule of Five” categories, which classify patients in stiffness increments combined with platelet count, track linearly with the risk of decompensation and death. A large retrospective study of over 17,000 U.S. veterans who had transient elastography found a stepwise increase in bad outcomes from “no cACLD” through “probable cACLD,” “certain cACLD without CSPH,” “probable CSPH,” and “certain CSPH.” Among those with certain CSPH (liver stiffness 25 kPa or above), patients whose stiffness reached 50 to 75 kPa had roughly double the risk of decompensation and death compared to those between 25 and 50 kPa, suggesting that even within the high-risk zone, further stratification is valuable.⁹

A separate multicentre study tested how well the 25 kPa cutoff predicted actual decompensation events over time. Patients meeting or exceeding that threshold had a cumulative incidence of decompensation of about 14% at one year and 23% at two years, compared to roughly 3% and 6% in those below it.¹⁰ These numbers make it clear that the 25 kPa line is not just an abstract threshold: it separates meaningfully different real-world trajectories.

Spleen Stiffness as an Emerging Tool

The spleen enlarges and stiffens as portal pressure rises, so measuring spleen stiffness has attracted attention as a complementary non-invasive marker. A 2018 meta-analysis showed excellent accuracy for diagnosing CSPH, with an area under the curve of 0.92.¹¹ In studies focused specifically on predicting dangerous varices, spleen stiffness outperformed other non-invasive parameters in both virus-related and non-virus-related portal hypertension.¹²

One practical advantage of spleen stiffness is its role in reducing unnecessary endoscopies. The standard way to check for dangerous esophageal varices is an upper endoscopy, but many patients screened this way turn out to have no varices requiring treatment. By adding spleen stiffness to algorithms already based on liver stiffness and platelet count, one study found that the number of patients who could safely avoid endoscopy jumped from about 34% with liver-based criteria alone to around 66 to 71%, without missing more than 5% of varices needing treatment.¹³ That is a meaningful reduction in procedures, costs, and patient inconvenience.

Finding cACLD Before It Reaches the Specialist

One of the biggest challenges with cACLD is that people who have it usually feel fine. They do not seek medical care for liver symptoms because they have none. This means the disease has to be found proactively, often through primary care screening in people with risk factors such as heavy alcohol use, obesity, diabetes, or viral hepatitis.

Simple blood-based scoring systems can serve as a first filter. The FIB-4 score, calculated from age, platelet count, and two liver enzymes already included in routine blood panels, is the most widely validated. One primary care referral pathway for patients with fatty liver disease used FIB-4 as the first step: a score below 1.30 kept patients in primary care with routine monitoring, a score above 3.25 triggered referral for specialist assessment, and scores in between received a second-tier blood test (the Enhanced Liver Fibrosis test) to decide whether referral was warranted.¹⁴ This two-step approach improved detection of advanced fibrosis and cirrhosis while cutting down on unnecessary referrals. A separate primary care screening study using FIB-4 found that roughly one in five patients flagged as positive actually had significant fibrosis when checked with more detailed tests, a rate consistent with transient elastography results.¹⁵

Where elastography is not readily available, ultrasound combined with basic blood markers can also help. One clinical algorithm found that a normal-looking liver on ultrasound paired with a normal albumin level and platelet count yielded a negative predictive value above 92% for cACLD, meaning that patients whose liver looks fine on imaging and whose blood tests are normal are very unlikely to have significant disease.¹⁶ That kind of reassurance matters in resource-limited settings where elastography machines are scarce.

Preventing the Slide Toward Decompensation

The most effective way to halt or reverse progression is to remove the underlying cause of liver injury. When the source of damage is effectively suppressed, whether that means curing hepatitis C, suppressing hepatitis B, or eliminating alcohol, regression of cirrhosis has been documented across both viral and non-viral etiologies.¹⁷ “Regression” does not always mean a full return to a normal liver, but it can mean enough reversal that portal pressure drops and the risk of complications falls substantially.

For patients who already have CSPH, a class of drugs called non-selective beta-blockers can lower portal pressure and reduce the risk of decompensation. Carvedilol, in particular, has accumulated strong evidence. A meta-analysis found that carvedilol cut the risk of decompensation roughly in half compared to controls, driven mainly by a reduced risk of ascites, and also lowered the risk of death.¹⁸ Real-world data has reinforced these findings: a propensity-matched study comparing carvedilol to propranolol found that carvedilol was associated with a significantly lower five-year risk of new decompensation events, including ascites, variceal bleeding, hepatic encephalopathy, and hepatorenal syndrome.¹⁹ Additional work using a non-invasive model to identify patients with high-risk CSPH showed that carvedilol-treated patients had lower rates of decompensation than untreated counterparts.²⁰

Lifestyle interventions also matter, especially for patients with metabolic-associated liver disease and obesity. A clinical trial found that sixteen weeks of combined diet and moderate exercise safely reduced both body weight and portal pressure in overweight and obese patients with cirrhosis and portal hypertension.²¹ This does not mean exercise reverses cirrhosis, but it suggests that weight loss in the right population can meaningfully lower the hemodynamic pressure that drives complications.

Liver Cancer Surveillance in cACLD

People with cACLD are at elevated risk for hepatocellular carcinoma (HCC), and deciding who needs regular surveillance and how often is an active area of research. In a prospective cohort followed for a median of about five and a half years, the yearly incidence of HCC among cACLD patients was 2.4%.²² But that average obscures wide variation. A study that developed a risk algorithm incorporating liver stiffness, platelet count, age, sex, and etiology found that high-risk patients had an HCC incidence of about 16% within two years, while low-risk patients were under 2%.²³ That kind of stratification could eventually spare many lower-risk cACLD patients from the burden of six-monthly ultrasound surveillance while concentrating resources on those most likely to benefit.

Quality of Life in the Compensated Stage

Because cACLD is defined by the absence of symptoms, there is sometimes an assumption that quality of life is unaffected. The evidence contradicts this. Studies consistently show that health-related quality of life is poorer in patients with chronic liver disease than in healthy populations, and cirrhotic patients fare worse than those with earlier-stage liver disease across multiple measurement tools.²⁴ Fatigue, worry about disease progression, sleep disturbances, and subtle cognitive changes can erode well-being even when the classical complications have not arrived. Recognizing this gap is important because patients who “look fine” on paper may be struggling in ways that do not show up on a lab report, and their concerns about energy and daily functioning deserve clinical attention even though their disease is technically compensated.

The Economics of Early Detection

Screening for a condition that people do not know they have always raises the question of cost. Multiple analyses across different countries and populations have found that non-invasive screening strategies for cACLD are cost-effective. Transient elastography screening produced favorable cost-effectiveness ratios across six prospective European and Asian cohorts, with the strongest results in populations at risk of alcohol-related liver disease and reasonable results even in the general population.²⁵ A Korean analysis of a two-step strategy, using FIB-4 first and then elastography in those flagged, also came in below standard willingness-to-pay thresholds, with the cost-effectiveness improving further when the cardiovascular and cancer-prevention benefits of the lifestyle interventions triggered by screening were factored in.²⁶

The Baveno criteria themselves have economic implications beyond screening. For patients already diagnosed with compensated cirrhosis, using liver stiffness and platelet count to decide who truly needs endoscopy, rather than scoping everyone, was cost-effective compared with universal endoscopy across analyses in the UK, Canada, and Spain.²⁷ In an era of stretched healthcare budgets, the ability to safely reduce endoscopies by a third or more while actually producing slightly better outcomes is hard to argue against.